Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adicet Bio Inc (NQ: ACET )

19.26 +0.68 (+3.66%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 2, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 476,289
Open 18.37
Bid (Size) 17.57 (1)
Ask (Size) 20.59 (1)
Prev. Close 18.58
Today's Range 18.01 - 19.29
52wk Range 9.540 - 21.87
Shares Outstanding 42,851,342
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Adicet Bio to Host Investor Webcast to Discuss Updated Clinical Data from Ongoing ADI-001 Phase 1 Trial in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire

Performance

YTD
+5.07%
+5.07%
1 Month
+11.59%
+11.59%
3 Month
+34.59%
+34.59%
6 Month
+67.48%
+67.48%
1 Year
+86.09%
+86.09%

More News

Read More
Adicet Bio to Present at the Virtual JMP Securities Hematology and Oncology Summit
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Appoints Nancy Boman, M.D., Ph.D., as Senior Vice President and Chief Regulatory Officer
From Adicet Bio, Inc.
Via Business Wire
Gamma Delta T Cell Therapy Market Could Reach $4 Billion As Biotechs Race To Get Breakthrough Cancer Treatment Approved
Via Benzinga
Why Foresight Autonomous Shares Jumped 33%; Here Are 83 Biggest Movers From Yesterday
Via Benzinga
Target, Holley, Ferroglobe And Other Big Losers From Wednesday
Via Benzinga
Adicet Reports Third Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Showcases Preclinical Data for Four New Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio to Present at the 2022 Jefferies London Healthcare Conference
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
Adicet Bio to Present Preclinical Data from Allogeneic Gamma Delta T Cell Pipeline Programs at The Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022
Via Benzinga
Why Aditxt Shares Dipped Over 58%; Here Are 82 Biggest Movers From Friday
Via Benzinga
Why NCR Is Trading Lower By Around 23%, Here Are 42 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Reports Second Quarter 2022 Financial Results and Provides Business Updates
From Adicet Bio, Inc.
Via Business Wire
7 Cheap Biotech Stocks to Buy Now
Via InvestorPlace
Adicet Bio to Present at Upcoming Investor Conferences
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Adicet Bio, Inc.
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.